oxytocin and Marfan-Syndrome

Women with Marfan syndrome (MFS) are at high risk for pregnancy-associated aortic dissection. Pathogenic models that singularly invoke hemodynamic stress are difficult to reconcile with predominant postnatal occurrence of aortic tear, often occurring weeks to months after delivery. In consideration of events that peak at term, are sustained after delivery, and might synergize with previously defined signaling pathways implicated in aneurysm progression, we examined the hormone oxytocin, which initiates uterine contraction and milk letdown for the duration of lactation through phosphorylation of extracellular signal-regulated kinase (ERK). In a mouse model of MFS that shows highly penetrant postnatal aortic dissection, risk was strongly attenuated by preventing lactation or use of an oxytocin receptor antagonist. Survival correlated inversely with the extent of ERK activation in the aortic wall, and strong protection was observed upon attenuation of ERK phosphorylation using an inhibitor of ERK kinase (MEK) or the U.S. Food and Drug Administration-approved medication hydralazine, offering potential therapeutic strategies for pregnancy-associated vascular catastrophe in the setting of MFS.

Topics: Adrenergic beta-Antagonists; Animals; Aorta; Aortic Dissection; Disease Models, Animal; Female; Hydralazine; Lactation; MAP Kinase Signaling System; Marfan Syndrome; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase Kinases; Oxytocin; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Propranolol; Protein Kinase Inhibitors; Survival Analysis